McCarthy Sean A. 4
4 · CytomX Therapeutics, Inc. · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
CytomX (CTMX) CEO Sean McCarthy Sells 118,969 Shares
What Happened
Sean A. McCarthy, CEO and Director of CytomX Therapeutics (CTMX), sold 118,969 shares on March 17, 2026 at $6.42 per share, generating proceeds of $764,138. The sale was marked as to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (RSUs), so it is a routine, non-investment-motivated sale rather than a new purchase.
Key Details
- Transaction date: 2026-03-17; Price: $6.42 per share; Shares sold: 118,969; Proceeds: $764,138. (Transaction code: S = Sale)
- Purpose: Sold solely to satisfy tax/government withholding obligations tied to RSU vesting (Footnote F1).
- Holdings referenced: filing notes inclusion of 457,500 RSUs (F2) and shares held by the Sean A. McCarthy 2018 Trust, of which he is trustee (F3).
- Shares owned after transaction: not specified in the Form 4 filing.
- Timeliness: Form 4 filed 2026-03-19 for a 2026-03-17 trade — filed within the usual Section 16 reporting window.
Context
This was a sale to cover tax withholding on vested RSUs (common executive administrative activity) rather than an open-market purchase indicating increased insider confidence. No 10b5-1 plan or other trading plan was referenced in the provided footnotes.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-17$6.42/sh−118,969$764,138→ 1,078,922 total
- 93,158(indirect: See footnote)
Common Stock
[F3]
Footnotes (3)
- [F1]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- [F2]Includes 457,500 RSUs.
- [F3]Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.